The antibodies bind to the CTLA-4, found on a cell's surface, and shut off the brake.

FORBES: Magazine Article

All of which would seem to leave Bayer in a bind: Slash margins to meet the U.S. government's price target or let the drug go off-patent early.

FORBES: Should Bayer Cut Prices To Protect A Patent?